MA33290B1 - Pipéridines substituées - Google Patents

Pipéridines substituées

Info

Publication number
MA33290B1
MA33290B1 MA34375A MA34375A MA33290B1 MA 33290 B1 MA33290 B1 MA 33290B1 MA 34375 A MA34375 A MA 34375A MA 34375 A MA34375 A MA 34375A MA 33290 B1 MA33290 B1 MA 33290B1
Authority
MA
Morocco
Prior art keywords
diseases
substituted piperidines
treating
preventing
piperidines
Prior art date
Application number
MA34375A
Other languages
English (en)
Inventor
Dirk Heimbach
Susanne Roehrig
Grande Yolanda Cancho
Eckhard Bender
Katja Zimmermann
Anja Buchmueller
Christoph Gerdes
Mark Jean Gnoth
Kersten Matthias Gericke
Mario Jeske
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MA33290B1 publication Critical patent/MA33290B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Non-Alcoholic Beverages (AREA)

Abstract

L'invention concerne de nouvelles pipéridines substituées, des procédés pour les produire, leur utilisation pour traiter et/ou prévenir des maladies, ainsi que leur utilisation pour produire des médicaments pour traiter et/ou prévenir des maladies, en particulier des maladies cardiovasculaires et des maladies tumorales.
MA34375A 2009-05-27 2010-05-19 Pipéridines substituées MA33290B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102009022896A DE102009022896A1 (de) 2009-05-27 2009-05-27 Substituierte Piperidine
PCT/EP2010/003059 WO2010136144A1 (fr) 2009-05-27 2010-05-19 Pipéridines substituées

Publications (1)

Publication Number Publication Date
MA33290B1 true MA33290B1 (fr) 2012-05-02

Family

ID=42543057

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34375A MA33290B1 (fr) 2009-05-27 2010-05-19 Pipéridines substituées

Country Status (28)

Country Link
US (2) US20120220563A1 (fr)
EP (1) EP2435427A1 (fr)
JP (1) JP5718320B2 (fr)
KR (1) KR20120044289A (fr)
CN (2) CN102596944B (fr)
AR (1) AR076692A1 (fr)
AU (1) AU2010252345A1 (fr)
BR (1) BRPI1012055A2 (fr)
CA (1) CA2763400A1 (fr)
CL (1) CL2011002965A1 (fr)
CO (1) CO6470823A2 (fr)
CR (1) CR20110628A (fr)
CU (1) CU20110215A7 (fr)
DE (1) DE102009022896A1 (fr)
DO (1) DOP2011000364A (fr)
EA (1) EA201190312A1 (fr)
EC (2) ECSP11011482A (fr)
GT (1) GT201100300A (fr)
IL (1) IL215901A0 (fr)
MA (1) MA33290B1 (fr)
MX (1) MX2011012505A (fr)
PE (1) PE20120934A1 (fr)
SG (1) SG175753A1 (fr)
TN (1) TN2011000595A1 (fr)
TW (1) TW201109326A (fr)
UY (2) UY32638A (fr)
WO (1) WO2010136144A1 (fr)
ZA (1) ZA201108565B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009014484A1 (de) 2009-03-23 2010-09-30 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102009022896A1 (de) 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102009022892A1 (de) * 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102009022894A1 (de) * 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
US9193709B2 (en) 2011-10-07 2015-11-24 Takeda Pharmaceutical Company Limited 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases
MX381425B (es) 2016-04-20 2025-03-12 Bristol Myers Squibb Co Compuestos heterociclicos biciclicos sustituidos.
JP7102404B2 (ja) 2016-11-03 2022-07-19 ブリストル－マイヤーズ スクイブ カンパニー 置換窒素含有化合物
US10501449B2 (en) 2017-06-01 2019-12-10 Bristol-Myers Squibb Company Substituted nitrogen containing compounds
WO2023044364A1 (fr) 2021-09-15 2023-03-23 Enko Chem, Inc. Inhibiteurs de protoporphyrinogène oxydase

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5767144A (en) * 1994-08-19 1998-06-16 Abbott Laboratories Endothelin antagonists
WO1997036873A1 (fr) 1996-04-03 1997-10-09 Merck & Co., Inc. Piperidines, pyrrolidines et hexahydro-1h-azepines declenchant la liberation de l'hormone de croissance
US6403612B2 (en) * 2000-01-31 2002-06-11 Merck & Co., Inc. Thrombin receptor antagonists
BR0213325A (pt) 2001-10-15 2004-10-13 Janssen Pharmaceutica Nv Derivados de 4-fenil-4-[1h-imidazol-2-il]-piperidina substituìda para a redução de dano isquêmico
AU2003224632A1 (en) * 2002-03-01 2003-09-16 Smithkline Beecham Corporation Hppars activators
CN1993128A (zh) * 2004-06-24 2007-07-04 因塞特公司 N－取代的哌啶及它们作为药物的用途
US8071624B2 (en) 2004-06-24 2011-12-06 Incyte Corporation N-substituted piperidines and their use as pharmaceuticals
EA200700118A1 (ru) 2004-06-24 2007-08-31 Инсайт Корпорейшн Амидосоединения и их применение в качестве лекарственных средств
JP2008504279A (ja) 2004-06-24 2008-02-14 インサイト・コーポレイション アミド化合物およびその医薬としての使用
EA200700251A1 (ru) 2004-08-10 2007-08-31 Инсайт Корпорейшн Амидосоединения и их применение в качестве фармацевтических средств
JP2007008913A (ja) * 2004-09-17 2007-01-18 Tanabe Seiyaku Co Ltd ピペリジン化合物およびその製法
DE102004045796A1 (de) * 2004-09-22 2006-03-23 Merck Patent Gmbh Arzneimittel enthaltend Carbonylverbindungen sowie deren Verwendung
DE102004061750A1 (de) * 2004-12-22 2006-07-06 Bayer Healthcare Ag Heteroaryl-substituierte Pyrazoline
WO2007038138A2 (fr) 2005-09-21 2007-04-05 Incyte Corporation Utilisation pharmaceutique de composes amido
EA200870216A1 (ru) 2006-01-31 2009-02-27 Инсайт Корпорейшн Амидо соединения и их применение в качестве лекарственных средств
US20070213311A1 (en) 2006-03-02 2007-09-13 Yun-Long Li Modulators of 11-beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
US20070293529A1 (en) 2006-05-01 2007-12-20 Yun-Long Li Tetrasubstituted ureas as modulators of 11-beta hydroxyl steroid dehydrogenase type 1
KR20100114018A (ko) 2007-11-30 2010-10-22 바이엘 쉐링 파마 악티엔게젤샤프트 헤테로아릴-치환된 피페리딘
DE102009014484A1 (de) * 2009-03-23 2010-09-30 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102009022896A1 (de) 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102009022897A1 (de) * 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102009022894A1 (de) * 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine

Also Published As

Publication number Publication date
US20120220563A1 (en) 2012-08-30
CN102596944B (zh) 2015-08-26
BRPI1012055A2 (pt) 2016-05-17
EP2435427A1 (fr) 2012-04-04
SG175753A1 (en) 2011-12-29
TW201109326A (en) 2011-03-16
MX2011012505A (es) 2011-12-14
WO2010136144A1 (fr) 2010-12-02
UY32638A (es) 2010-10-29
ZA201108565B (en) 2013-01-30
TN2011000595A1 (en) 2013-05-24
PE20120934A1 (es) 2012-08-01
US8084469B2 (en) 2011-12-27
JP2012528090A (ja) 2012-11-12
CR20110628A (es) 2012-03-22
GT201100300A (es) 2013-08-21
CN102596944A (zh) 2012-07-18
UY32636A (es) 2010-12-31
ECSP11011483A (es) 2011-12-30
CN104744452A (zh) 2015-07-01
ECSP11011482A (es) 2011-12-30
US20110021489A1 (en) 2011-01-27
KR20120044289A (ko) 2012-05-07
DOP2011000364A (es) 2012-02-29
CL2011002965A1 (es) 2012-07-06
DE102009022896A1 (de) 2010-12-02
EA201190312A1 (ru) 2012-05-30
AR076692A1 (es) 2011-06-29
JP5718320B2 (ja) 2015-05-13
CO6470823A2 (es) 2012-06-29
IL215901A0 (en) 2012-01-31
CU20110215A7 (es) 2012-03-15
CA2763400A1 (fr) 2010-12-02
AU2010252345A1 (en) 2011-12-08

Similar Documents

Publication Publication Date Title
MA33290B1 (fr) Pipéridines substituées
UA102065C2 (en) Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof
MY173616A (en) Compositions and methods for lowering triglycerides
MX2011009539A (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso.
PH12013502192A1 (en) Antibodies against human angiopoietin 2
MY159375A (en) Combinatorial therapy
MX2012004551A (es) Nuevas composiciones para prevenir y/o tratar trastornos de almacenamiento lisosomal.
MY151191A (en) Novel antibodies
WO2009068214A3 (fr) Pipéridines à substitution hétéroaryl
MA33291B1 (fr) Pipéridines substituées
MA34248B1 (fr) 5-fluoro-1h-pyrazolopyridines substituées et leur utilisation
IN2012DN02737A (fr)
EP2438178A4 (fr) Micro-organismes pour la production de 1,4-butanediol et procédés afférents
EA201001639A1 (ru) Композиции и способы их получения и применения
JO2931B1 (en) Double-substituted phthalazin compounds as antagonists of the cell-specific factor pathway
MA38060A1 (fr) Imidazo[1,2-a]pyridincarboxamides amino-substitués et leur utilisation
MY159491A (en) Disubstituted phthalazine hedgehog pathway antagonists
EA201170753A1 (ru) Налмефена гидрохлорид дигидрат
WO2009115252A3 (fr) Pyrazolamides substitués et leur utilisation
MX2012000572A (es) Moduladores del receptor 5-hidroxi triptamina 3 (5-ht3), metodos para su realización y uso de los mismos.
MY164998A (en) Isoquinolinone derivatives as nk3 antagonists
MY149864A (en) Flavouring-containing pharmaceutical formulations with improved pharmaceutical properties
MA37700B1 (fr) N-[4-(quinolin-4-yloxy)cyclohexyl(méthyl)](hétéro)arylcarboxamides utilisables en tant qu'antagonistes des récepteurs aux androgènes, leur production et leur utilisation en tant que médicaments
TW200745132A (en) Novel, acyclically substituted furopyrimidine derivatives and use thereof
MX2007005526A (es) Tratamiento de mastitis con enrofloxacino.